TCM Biotech International Corp.
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceutica… Read more
TCM Biotech International Corp. (4169) - Net Assets
Latest net assets as of September 2025: NT$1.06 Billion TWD
Based on the latest financial reports, TCM Biotech International Corp. (4169) has net assets worth NT$1.06 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.18 Billion) and total liabilities (NT$118.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.06 Billion |
| % of Total Assets | 89.96% |
| Annual Growth Rate | 15.7% |
| 5-Year Change | 104.76% |
| 10-Year Change | N/A |
| Growth Volatility | 38.11 |
TCM Biotech International Corp. - Net Assets Trend (2019–2024)
This chart illustrates how TCM Biotech International Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TCM Biotech International Corp. (2019–2024)
The table below shows the annual net assets of TCM Biotech International Corp. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.06 Billion | +0.38% |
| 2023-12-31 | NT$1.06 Billion | +96.59% |
| 2022-12-31 | NT$536.67 Million | +3.56% |
| 2021-12-31 | NT$518.22 Million | +0.19% |
| 2020-12-31 | NT$517.24 Million | +1.28% |
| 2019-12-31 | NT$510.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TCM Biotech International Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$29.53 Million | 2.79% |
| Common Stock | NT$590.49 Million | 55.75% |
| Other Components | NT$439.06 Million | 41.46% |
| Total Equity | NT$1.06 Billion | 100.00% |
TCM Biotech International Corp. Competitors by Market Cap
The table below lists competitors of TCM Biotech International Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
V-Mart Retail Limited
NSE:VMART
|
$224.87 Million |
|
Haitian Water Group Co.Ltd
SHG:603759
|
$225.00 Million |
|
Song Chuan Precision Co., Ltd.
TW:7788
|
$225.01 Million |
|
Kung Long Batteries Industrial Co Ltd
TW:1537
|
$225.04 Million |
|
Lungteh Shipbldg Co Ltd
TW:6753
|
$224.84 Million |
|
Caribbean Utilities Company Ltd
PINK:CUPUF
|
$224.77 Million |
|
Hanilcmt Co Ltd
KO:300720
|
$224.74 Million |
|
Agesa Hayat ve Emeklilik AS
IS:AGESA
|
$224.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TCM Biotech International Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,055,042,000 to 1,059,079,000, a change of 4,037,000 (0.4%).
- Net income of 21,010,000 contributed positively to equity growth.
- Dividend payments of 16,829,000 reduced retained earnings.
- Other comprehensive income increased equity by 69,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$21.01 Million | +1.98% |
| Dividends Paid | NT$16.83 Million | -1.59% |
| Other Comprehensive Income | NT$69.00K | +0.01% |
| Other Changes | NT$-213.00K | -0.02% |
| Total Change | NT$- | 0.38% |
Book Value vs Market Value Analysis
This analysis compares TCM Biotech International Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.91x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.35x to 10.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$10.10 | NT$195.50 | x |
| 2020-12-31 | NT$10.24 | NT$195.50 | x |
| 2021-12-31 | NT$10.21 | NT$195.50 | x |
| 2022-12-31 | NT$10.93 | NT$195.50 | x |
| 2023-12-31 | NT$19.89 | NT$195.50 | x |
| 2024-12-31 | NT$17.93 | NT$195.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TCM Biotech International Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.15%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.12x
- Recent ROE (1.98%) is below the historical average (2.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 1.28% | 1.15% | 0.74x | 1.50x | NT$-44.56 Million |
| 2020 | 4.94% | 3.47% | 0.95x | 1.49x | NT$-26.18 Million |
| 2021 | 0.36% | 0.27% | 0.86x | 1.58x | NT$-49.95 Million |
| 2022 | 3.40% | 2.28% | 0.93x | 1.61x | NT$-35.40 Million |
| 2023 | 1.76% | 1.92% | 0.73x | 1.25x | NT$-86.93 Million |
| 2024 | 1.98% | 3.15% | 0.56x | 1.12x | NT$-84.90 Million |
Industry Comparison
This section compares TCM Biotech International Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,107,525,400
- Average return on equity (ROE) among peers: 2.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TCM Biotech International Corp. (4169) | NT$1.06 Billion | 1.28% | 0.11x | $224.86 Million |
| Synbio Tech Inc. (1295) | $942.97 Million | 12.01% | 1.00x | $21.72K |
| Apex Biotechnology Corp (1733) | $842.42 Million | 19.18% | 0.14x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $875.36 Million | 7.09% | 0.89x | $129.07 Million |
| Panion & BF Biotech Inc (1760) | $278.86 Million | -14.55% | 2.31x | $123.88 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.02 Billion | 5.81% | 0.71x | $42.95 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.16 Billion | 13.75% | 0.60x | $45.13 Million |
| Level Biotechnology (3118) | $498.78 Million | 7.80% | 0.36x | $22.63 Million |
| GenMont Biotech Inc (3164) | $861.62 Million | 3.30% | 0.66x | $31.27 Million |
| Medigen Biotechnology (3176) | $3.18 Billion | -14.68% | 0.53x | $100.57 Million |
| Sagittarius Life Science (3205) | $419.76 Million | -11.56% | 0.24x | $56.40 Million |